101 
Market Cap
Stock Chart
Benitec - 30 Day Poll
Recent BLOGS About Benitec Add New
Latest Company News
|
Benitec Ltd. Announces Issue Of Shares Pursuant To Conversion Of Convertible Note.
Reuters Key Development - Jul 28, 2010 |
|
Benitec Limited (ASX:BLT) Continues To Expand Patent Portfolio In Gene Expression Around The World
Asia Business News - Jul 14, 2010 Melbourne, July 14, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to provide this update on the progress of the patent family "Control of Gene Expression" in a number of ...
|
|
Benitec Limited (ASX:BLT) Granted Hepatitis C RNA Interference Patent In US
Asia Business News - Jun 18, 2010 Melbourne, June 18, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to announce that US Patent 7727970 "Multiple promoter expression cassettes for simultaneous delivery of ...
|
|
Benitec Ltd. Granted Hepatitis C RNA Interference Patent In US
Reuters Key Development - Jun 18, 2010 |
|
Benitec Limited (ASX:BLT) HIV/AIDS Stem Cell Clinical Trial Results Published In Science-Translational Medicine
ABN Newswire - Jun 17, 2010 Melbourne, June 17, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to announce that the results of Benitec's US-based HIV/AIDS pilot clinical trial have been published in ...
Benitec Limited HIV/AIDS Stem Cell Clinical Trial Results Published In Science-Translational Medicine - PharmaLive |
|
Benitec Limited (ASX:BLT) DNA-Directed RNAi Technology Suppresses BIII-Tubulin In A Human Lung Cancer Model
Asia Business News - Jun 15, 2010 Sydney, June 16, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF) are pleased to announce the publication of a paper in the prestigious scientific journal Cancer Research by Associate ...
|
Website
Videos related to Benitec
Company Profile
Revenue 2009 financial year: $362,000
Cash and cash equivalents June 30th 2009 was $1,866,605
Benitec is a ribonucleic acid interference (RNAi)-based therapeutics company using its deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi) technology to develop therapies for the treatment of life threatening diseases.
The Company’s primary therapeutic program focuses on human immunodeficiency virus (HIV). Its other projects are in the area of infectious diseases and cancer.
It also licenses its technology outside of its in-house programs in order to generate revenue to support its corporate and operational activities.
Key research relationships (formal and informal) currently exist with the following groups in the areas of target
identification and delivery technology:
- Division of Molecular Biology: City of Hope (Duarte, California USA);
- Gene & Stem Cell Therapy Group: Centenary Institute of Cancer Medicine and Cell Biology (NSW Australia);
- Gene Therapy Research Unit: Children’s Medical Research Institute & Westmead Children’s Hospital (NSW Australia);
- Centre for Reproduction and Development: Monash Institute of Medical Research (Victoria Australia)
- Biomics Biotechnology Nantong, China.
During the fiscal year ended June 30, 2009 (fiscal 2009), the principal activity of the Company was the management, funding and commercialization of these projects. It operates in a single segment, including global commercialization (by licensing and partnering) of patents and licenses developed in the area of biotechnology, specifically in functional genomics, with applications in biomedical research and human therapeutics.
Some leading players in the same field:
- Merck see our sister USA website
- Tekmira Pharmaceuticals
- Silence Therapeutics